The majority of drug discovery will be conducted in silico.
Business models will be radically different. - Biotechs dominate innovation - Pharmas are distributors - Governments are the major customers
Healthcare will be centrally delivered. - The $1,000 genome will be a reality - Smart cards will contain a person’s genome and health records - Individual decision-making will be embraced in the new healthcare system
Combination therapies - We will know more about the “circuit” diagrams of disease and new medicines will combine a diagnostic (safety) with a drug along with a delivery device (compliance)
Spare parts - Driven by progress in stem cells and regenerative medicine
Wellness - The pendulum will swing to prediction and prevention driven by employers rewarding its employees for engaging in fitness and wellness programs - There will be a robust nutraceuticals industry
Agbio - Transgenics becomes mainstream - Countries develop own GM technology/no longer at whim of multinationals - GM growth holds steady - Plant made pharmaceuticals become a reality
Industrial Biotechnology - By 2020, environmental issues will drive biofuel economy - Growth trend for biomaterials—feedstocks become less reliant on fossil fuels, more on renewable
